Germany-based company acquires lino Biotech

Founded in 2020 as a spinoff of the ETH, lino Biotech is a leading biosensor company and the world’s only provider of Focal Molography – a new method for measuring molecular interactions in living cells or crude biological samples. Following its acquisition by Miltenyi Biotec, the startup will remain at its headquarters in Zurich.

Lino Biotech is a life science tools company backed by Roche Venture Fund, High-Tech Gründerfonds and several life science family offices. The company develops reagent-free biosensors and readers to measure pharmaceutical-relevant biological entities directly from crude samples such as bioprocess reactors solutions. The platform facilitates quality control in bioprocessing, measuring viral load in cell and gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery. Its ability to provide target-specific binding information faster, sensitively and cost-effectively can lower R&D and production costs for pharma and biotech customers and offer an opportunity to make novel Cell & Gene therapies accessible to more patients.

The startup’s journey continues under the family of Miltenyi Biotec, a Bergisch Gladbach-based company and global provider of products and services for biomedical research and cellular therapy for over 30 years. The company has more than 4,500 employees in 28 countries.

Under the terms of the transaction, Miltenyi Biotech will acquire 100% of the shares from the investors. The startup’s Zurich headquarters will be further expanded for research, chip, and application development.

“lino´s innovative biosensor platform and Miltenyi’s cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays,” said Mirko Stange, CEO of lino Biotech.